Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
To determine the recommended Phase IIa dose (RP2D) of the triplet combination.
To determine the safety and efficacy of the combination at the RP2D.
Trial Details
- NCT ID
- NCT06683755
- Phase
- PHASE1 / PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Melanoma
- Interventions
- Nivolumab
- Relatlimab
- Ipilimumab
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Age ≥ 18 years old.
- ECOG performance status 0-1
- Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. T…
- Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Melanoma Trials on Trialify →